Yatharth Hospital FY26 Revenue Surges 36% to ₹1,207 Cr; Expands Bed Capacity

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorAnanya Iyer|Published at:
Yatharth Hospital FY26 Revenue Surges 36% to ₹1,207 Cr; Expands Bed Capacity
Overview

Yatharth Hospital reported strong FY26 results with a 36% revenue jump to ₹1,207 crore. The company is expanding capacity to 5,000 beds and plans a new Gurugram facility by April 2027. Investors are watching expansion progress and governance improvements.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

Yatharth Hospital FY26 Results: Robust Growth and Strategic Expansion

FY26 Revenue: ₹1,207.2 crore
Q4 FY26 Revenue: ₹341.6 crore

Reader Takeaway: Strong revenue growth and capacity expansion are positive; competitive market and payer mix are watch points.

What just happened

Yatharth Hospital & Trauma Care Services Ltd. announced its financial results for FY26, reporting a consolidated revenue of ₹1,207.2 crore, marking a significant 36% year-over-year increase. The fourth quarter of FY26 (Q4 FY26) also showed robust growth, with revenue up 47% year-over-year to ₹341.6 crore. EBITDA for FY26 stood at ₹292.1 crore, and Profit After Tax (PAT) was ₹170.3 crore. The occupancy rate for Q4 FY26 was 71%.

Why this matters

These results highlight Yatharth Hospital's ability to drive revenue growth through a combination of organic expansion and operational efficiency. The significant year-over-year increases in revenue suggest successful integration of new facilities and strong performance in existing ones. The company's focus on increasing bed capacity and strategic expansion in North India indicates a clear growth path.

The backstory

The company has been pursuing a cluster-based expansion strategy, particularly in North India. Its current capacity is over 3,200 beds, with a target to reach 5,000 beds within the next three years. A key part of this expansion is the acquisition of an under-construction facility in Gurugram, expected to be operational by April 2027.

What changes now

With these strong results and a clear expansion roadmap, Yatharth Hospital is positioned to continue its growth trajectory. The company is also focusing on strengthening corporate governance, with recent appointments including new statutory and internal auditors, and an independent director. Improvements in debtor days to 112 days are also noted.

Risks to watch

The company operates in a highly competitive market, especially the NCR region. A significant portion of revenue (around 35%) still comes from government-related schemes, although the company aims to reduce this dependency. Minor impacts from oncology drug price capping were also mentioned.

Peer comparison

While specific peer financial data is not provided in the filing, the healthcare sector in India is competitive. Yatharth Hospital's focus on expansion and operational efficiency, including debt management, is crucial for maintaining its market position against other hospital chains.

Context metrics (time-bound)

  • FY26 Revenue: ₹1,207.2 crore (up 36% YoY)
  • Q4 FY26 Revenue: ₹341.6 crore (up 47% YoY)
  • FY26 EBITDA: ₹292.1 crore
  • FY26 PAT: ₹170.3 crore
  • Q4 FY26 Occupancy Rate: 71%
  • Gross Debt (as of March 31, 2026): ₹230 crore
  • Net Debt (as of March 31, 2026): ₹116 crore

What to track next

Investors will be keen to monitor the progress of the Gurugram facility's construction and its timeline to operationalization. The company's ability to further improve debtor days and manage its payer mix will also be important indicators of future performance.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.